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Background: To enhance usage of health technology assessment (HTA) in decision-making, it is 
important to prioritise important barriers and facilitators to the uptake of HTA. This study aims to 
quantify and compare the relative importance of barriers and facilitators regarding the use of HTA in 
several European countries. 
 
Methods: A survey containing two best-worst scaling (BWS) object case studies (i.e. barriers and 
facilitators) were conducted among 136 policy makers and HTA researchers from the Netherlands, 
Germany, France, and United Kingdom. Hierarchical Bayes analysis generated the mean relative 
importance score (RIS) for each factor and subgroup analyses assessed differences between countries. 
 
Findings: Six barriers (RIS≥5) and five facilitators (RIS≥6) were deemed highly important. Eleven barriers 
and ten facilitators differed in their importance between countries. Policy characteristics, research & 
researcher characteristics, and organisation & resources were particularly important to facilitate 
uptake of HTA, such as an explicit framework for decision-making and research of sufficient quality. 
 
Discussion: The most paramount barriers and facilitators to HTA usage were quantified. For all 
countries it is crucial to create an explicit framework for the decision-making context to include HTA 
evidence. Country differences in the quality of research emphasize the need for enhanced 





Due to increasing economic concern, health policy makers need to efficiently allocate resources or 
select cost-effective health interventions [1]. Health technology assessment (HTA) - a multidisciplinary 
research field to evaluate the social, economic, organizational and ethical issues of a health 
intervention (e.g. drugs, medical devices, public health) – aims to facilitate this decision-making 
process to inform how to obtain value for money [2]. HTA is a policy-oriented form of research 
designed to inform decision-makers on the relative effectiveness or cost-effectiveness of a new 
technology compared to current or best practice [3]. Although both the number of public health 
interventions as well as the number of HTA studies is increasing [4, 5], the uptake of HTA information 
in the decision-making could be improved [5, 6, 7].  
Due to the relatively young nature of the HTA discipline, scholars do not yet fully understand 
what may hinder and facilitate the usage of HTA in decision-making and to what extent. Various studies 
including systematic reviews have been conducted to identify multiple barriers and facilitators to the 
uptake of HTA information, such as sufficient quality and timeliness of HTA research [4, 5, 8, 9, 10, 11, 
12]. However, being aware of the relative importance of each of these factors would provide more 
guidance to bridge the gap between research and policy. A recent Dutch study identified the most 
important barriers and facilitators for using HTA in decision-making, using the best-worst scaling (BWS) 
method [13]. This study suggested that ’policy characteristics’, and ‘organisation and resources’ were 
particularly important to enhance HTA usage, especially the creation of an explicit framework for the 
decision-making context including HTA. Despite these valuable insights to the position in the 
Netherlands, it is important to understand to what extent the relative importance of these factors 
could be generalizable to other countries, with different decision-making contexts. Countries in Europe 
and worldwide differ in their level and trends in HTA development [7]. To what extent European 
countries differ regarding the most important factors and their relative ranking needs yet to be 
investigated.  
Hence, to deepen our understanding of how to enhance HTA uptake in policy making, this 
study aims to (1) identify the most important barriers and facilitators to HTA usage in the decision-
making context in four European countries (i.e. Netherlands, Germany, France, and United Kingdom), 








In order to elicit expert opinion on the importance and the relative weight of a large list of barriers and 
facilitators to the use of HTA, we used the BWS method. The BWS method is an increasingly popular 
conjoint analysis technique [14, 15], devised by Finn and Louviere (1992) [16], having some advantages 
compared to other methods (such as discrete choice experiments). The BWS method also collects data 
on the ‘worst’ option, as well as the ‘best’ option, resulting in a method capable of incorporating a 
larger set of factors [14, 17], while the object case was shown to be cognitively less burdensome 
compared to discrete choice experiments for participants [18]. To quantify the relative importance of 
barriers and facilitators for the use of HTA in policy decisions, this study used the BWS object case. 
Participants were asked to complete a series of choice tasks in which they had to choose the most and 
least important factor (i.e. barrier or facilitator) from a list of five factors, derived from a master list.  
 
Participants 
Country-specific researchers (i.e. KLC (Netherlands), JW & LK (Germany), PL (France), and TJ (United 
Kingdom)) identified policy makers (i.e. decision makers and advisors on different levels) and HTA 
experts (i.e. PhD students and senior researchers in HTA) via convenience sampling. Each country-
specific researcher created a list of potential stakeholders in their country based on a search of the 
relevant health institutes and HTA research departments of several universities, enriched by personal 
networks. Potential participants were then approached via e-mail, which included a link to the survey 
(on the Qualtrics platform) which randomly assigned the participant to one of the four versions of the 
questionnaire for each survey (i.e. barriers and facilitators). A reminder was sent within two weeks to 
participants who had not completed the survey. All participants were approached between November 
2015 and May 2017 (i.e. Netherlands; n=222, Germany; n=365, France; n=109, and United Kingdom; 
n=255). 
 
Identification of barriers and facilitators 
The master list of factors was drafted based on a scoping review and expert validation in the previous 
Dutch study [13]. For this, a scoping review using PubMed and Web of Science was conducted to 
identify important barriers and facilitators regarding the uptake of HTA [4, 5, 8, 9, 10, 11, 12, 19, 20, 
21, 22, 23, 24, 25, 26, 27]. Further details on the search and the selection of attributes can be found in 
Cheung et al. (2017) [13]. We then defined and validated the list of factors for inclusion in this study. 
The list of factors was extensively discussed among the working group (i.e. KLC, SE, HdV, and MH), and 
external experts (two HTA experts and one policy maker) were asked to provide feedback on the list 
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regarding (1) completeness, (2) overlap, and (3) wording. This led to a final list of 22 barriers and 19 
facilitators for the BWS survey (see Supplementary file 1).  
 
The best-worst scaling survey 
Two surveys (i.e. one for the barriers, one for the facilitators) were designed using the Sawtooth 
Software’s SSI Web platform; resulting in fractional, efficient designs (which are characterised by 
orthogonality, minimal overlap, positional balance, connectivity, and stability). For each survey four 
different versions (i.e. different design of the choice-sets) of the questionnaires were used, with 14 
choice sets for the barriers and 12 choice sets for the facilitators. The survey consisted of three parts: 
(1) demographics, (2) barriers, and (3) facilitators; barriers and facilitators were not in a particular 
order due to randomisation. Qualtrics was used to administer the online survey, and participants were 
recruited via e-mail. First, participants were asked for their age, gender, and their role (policy maker, 
HTA expert). Second, Qualtrics then randomised participants to one version of the barriers 
questionnaire and one version of the facilitators questionnaire. Participants were asked to choose the 
most important and the least important factor to the uptake of HTA in 14 choice sets for the barriers 
and 12 choice sets for the facilitators, each consisting of five factors from the master list (22 factors 
for the barriers and 19 factors for the facilitators). In addition, participants were asked to rate the 
difficulty of the choice tasks using a Likert scale (0 = very easy to 7 = very difficult), for both surveys.  
Supplementary files 2 (barriers) and 3 (facilitators) illustrate the BWS choice sets, including the 
introductory text. The survey was finalised after a pilot with three HTA experts from Maastricht 
University, and the survey was used in a previous study with the BWS application in the Netherlands 
[13]. The estimated time to complete the survey is approximately 25 minutes. This survey was then 
translated to French and German by one or two researchers per country. This version was piloted by 
five HTA researchers (n=2 for France, n=3 for Germany), resulting in minor adjustments without 
changing the scientific methodology and content. 
 
Analyses 
The analyses were conducted for all completed responses. First, descriptive statistics were calculated 
to present demographic characteristics of the respondents. Second, to analyse preference data, 
Hierarchical Bayes analysis [14, 28, 29] was conducted (using Sawtooth Software’s SSI Web platform), 
which is frequently used to analyse BWS studies in the literature [15]. The mean relative importance 
score (RIS) with its 95% confidence interval was calculated for each factor. Rescaled scores were 
estimated, based on the raw coefficient of the preference function, which represents the probability 
that the respondent chooses the factor. All factors combined the RIS for each individual sum up to 100, 
with a higher score indicating a relatively higher importance of the factor [29]. A RIS of ‘10’ represents 
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a two-fold higher importance than a RIS of ‘5’. Fit statistic was used to identify inconsistent responders. 
Using the mean RIS, factors were ranked from most to least important for the uptake of HTA in policy 
making. The individual’s fit statistic was used to check the quality of the responses, with a fit statistic 
lower than 0.25 indicating purely random responses to the choice tasks [30]. In order to check the 
sensitivity of results, the best-worst count analysis was conducted [20], Last, one-way ANOVA analyses 
per factor were used for subgroup analyses on ‘country’ and ‘role’ to explore whether the perceptions 
on the importance of these factors differ among different countries and roles, and where the 
differences lie. Post-hoc analyses were conducted to identify specific country differences, using Tukey 
honest significant difference (HSD) tests. When homogeneity assumptions were violated, the Welch 





In total, 298 stakeholders started the survey, of which 136 (45.8%) actually completed the survey. Of 
the 162 incomplete responses, 129 responses (80%) contained complete information on the 
demographic characteristics (i.e. gender, age, and role). Participants who completed the survey did 
not significantly differ from participants who dropped out, except for in terms of their ‘role’ (defined 
as either policy maker or HTA researcher). Policy makers dropped out significantly more than HTA 
researchers (2(1, N = 265) = 6.17, p = 0.01). Stakeholders rated both BWS experiments as moderately 
difficult on a 7-point Likert scale (barriers, Mean=4.54, SD=1.38; facilitators, Mean=4.54, SD=1.38). 
Table 1 provides information on the demographic characteristics (i.e. gender, age, and role). 
 
Relative importance of the barriers  
The RIS scores of the barriers, overall and for each country, are depicted in Table 2. First, we identified 
the overall most important barriers to HTA usage in the decision-making context. Overall, a cut-off RIS 
score of 5 shows six highly important barriers: (1) No explicit framework for decision making process 
(that uses HTA evidence), (2) Limited generalizability (of HTA studies to the policy maker’s context), (3) 
No availability of relevant HTA research (for policy makers), (4) Lack of consensus between HTA 
findings (existence of different and opposing recommendations), (5) Insufficient quality (of HTA 
research findings: quality not according scientific requirements), and (6) No access to relevant HTA 
research (or poor dissemination) for policy makers.  
Second, we explored the potential country differences. Subgroup analyses revealed that 11 
barriers differed in their importance between countries: (1) Lack of timeliness of research, (2) Lack of 
longstanding relation between professionals/policymakers and researchers, (3) Lack of contact and 
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interaction, among policy-makers, HTA researchers, and other stakeholders, (4) No availability of 
relevant HTA research for policy makers, (5) No access to relevant HTA research (or poor 
dissemination) for policy makers, (6) Absence of policy networks, (7) Lack of support, within the 
organization to the use of HTA, (8) Insufficient quality, of HTA research findings: quality not according 
scientific requirements, (9) Policy-maker's perception of insufficient support by end-users (e.g. patient 
associations), (10) Lack of legal or legislative support to the use of HTA, and (11) Absence of 
appropriate incentives, for implementation of cost-effective interventions. Remarkable country 
differences were ‘Insufficient support by stakeholders’ (i.e. Netherlands with a noticeably higher RIS 
scores than the other countries) and ‘No availability of relevant HTA research’ (i.e. Netherlands with a 
noticeably lower RIS scores than the other countries). 
For policy makers specifically, subgroup analyses showed seven significant differences in RIS 
scores between countries for policy makers (see Figure 1): (1) Lack of longstanding relation (NL,DE>FR), 
(2) Lack of contact and interaction (NL>FR), (3) No availability of relevant HTA research (DE,FR>NL), (4) 
Absence of policy networks (NL,DE>FR), (5) Insufficient support by stakeholders (NL>DE,FR,UK), (6) 
Insufficient quality, of HTA research findings (DE,FR>NL), and (7) Insufficient legal support 
(NL>DE,FR,UK). The best-worst count analysis revealed a similar ranking (slight differences) (results 
available upon requests from the corresponding author). Supplementary file 4 details additional 
analyses. 
 
Relative importance of the facilitators  
The RIS scores of the facilitators, overall and for each country, are depicted in Table 3. First, the overall 
most important facilitators to HTA usage in the decision-making context were identified. When a cut-
off RIS score of 6 is used (which is different from the barriers due to fewer factors resulting into higher 
RIS scores per factor), overall five facilitators were deemed highly important by the participants: (1) 
Sufficient quality, (2) Availability of explicit framework for decision making process, (3) Availability to 
relevant HTA research, (4) Sufficient qualified human resources, and (5) Higher transparency of HTA 
research findings.  
Second, potential country differences were investigated. Subgroup analyses showed that ten 
facilitators significantly differed in their importance between countries; (1) Improving longstanding 
relation, (2) Sufficient legal support, (3) More personal contact and interaction, (4) Sufficient support 
by stakeholders, (5) Creation of policy networks, (6) Availability of guidelines, (7) Appropriate 
incentives, (8) Access to relevant HTA research, (9) Availability to relevant HTA research, and (10) 
Sufficient quality. In line with the barriers, remarkable country differences were ‘Availability of relevant 
HTA research’ and ‘Sufficient support by stakeholders’. 
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Regarding policy makers only, subgroup analyses revealed seven significant differences in RIS 
scores between countries, which were: (1) ‘Sufficient quality’ (DE,FR>NL), (2) ‘Sufficient credibility’ 
(DE>NL), (3) ‘Improving longstanding relation’ (NL,DE>FR), (4) ‘Creation of policy networks’ (NL>FR), 
(5) ‘More personal contact and interaction’ (NL,DE>FR), (6) ‘Sufficient support by stakeholders’ 
(NL>DE,UK,FR), and (7) ‘Availability of guidelines’ (FR>NL,DE) (see Figure 2). The best-worst count 
analysis [20] revealed a similar ranking (slight differences) (results available upon requests from the 




This study aimed to identify the most important barriers and facilitators to HTA usage in the decision-
making context in four European countries and to explore potential country differences. Overall, the 
most important barrier is the lack of an explicit framework for the decision making process (that uses 
HTA evidence). At the same time, the availability of an explicit framework for the decision making 
process (that uses HTA evidence) is among the most important facilitators. This is in line with findings 
from García-Mochón et al. (2017) [31], suggesting that a prerequisite for the adoption of HTA evidence 
is a transparent and comprehensive system, and therefore of utmost importance to facilitate its usage 
in decision-making. 
Based on the most important barriers, it seems that – as categorised by Oliver et al. (2014) [5] 
– policy characteristics (e.g. ‘No explicit framework’), research and researcher characteristics (e.g. 
‘Limited generalizability’, ‘Lack of consensus between HTA findings’, ‘No availability of relevant HTA 
research’, and ‘Insufficient quality’), and organisation and resources (e.g. ‘No access to relevant HTA 
research’) are important to tackle to enhance HTA usage. Next to the availability of an explicit 
framework, the most important facilitators overall were: ‘Sufficient quality’, ‘Availability to relevant 
HTA research’, ‘Sufficient qualified human resources’, and ‘Higher transparency of HTA research 
findings’; again pointing at the importance of addressing policy characteristics, research and 
researcher characteristics, and organisation and resources, as found for barriers and as categorised by 
Oliver et al. (2014) [5]. Similarly to the previous study in the Netherlands [13], many of the most 
important barriers paralleled the facilitators, meaning that the most important facilitators were the 
factors that targeted the most important barriers. For instance the barrier ‘Insufficient quality’ (of HTA 
studies), and the facilitator ‘Sufficient quality’ (of HTA studies) were both among the most important 
factors. Findings indicate a lack of qualified human resources to conduct or understand relevant HTA 
research within the policy organization, suggesting the need to improve capability in health economics 
by employing more health economists and providing further training for policy makers. It seems that 
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over the years, the quality of HTA studies and lack of qualified people have remained important issues 
to address. This finding is consistent with a study from 2010, indicating the need for more training in 
health economics, and the lack of quality [32].  
This study further identified the country differences regarding the relative importance of the 
barriers and facilitators. Differences were found in several barriers and facilitators, such as in the 
importance of the availability of relevant HTA research. The Netherlands markedly differ from the 
other countries where the availability of relevant HTA is among the most important facilitators. In 
addition, overall the quality of HTA studies is deemed the most important facilitator. All countries seem 
to agree that it is both, an important barrier and facilitator, yet Dutch participants prioritised sufficient 
quality significantly lower than the German participants. For instance, compared to Germany, Dutch 
participants perceived having appropriate incentives for implementation of cost-effective 
interventions, and the availability of an explicit framework for decision making process more important 
than sufficient quality of HTA research. Countries generally differ in their level and trends in HTA 
development (e.g. the UK having an advanced HTA program) [7]. Perhaps the country difference 
regarding the (lack of) sufficient quality is due to differences in HTA development between these 
countries, with for example the Netherlands having a long tradition in establishing a comprehensive 
HTA program. Overall, the high importance and heterogeneity of ‘insufficient quality of HTA research’ 
and ‘availability of relevant HTA research’ indicate the need for enhanced international collaboration 
in HTA. Due to sharing experience, skills, and methodology, international collaboration is an efficient 
way to increase e.g. the variety of high-quality HTA information and the number of timely national HTA 
reports [3, 22, 33, 34]. In a study on the collaboration in HTA (EUnetHTA joint action 2010-2012), 
facilitating factors were suggested to enhance international collaboration, e.g. merging 
methodological and clinical expertise, and acceptance of English-written reports by decision makers 
[22]. As indicated in a study from 2000, credibility of HTA studies is an important factor to enhance 
usage of HTA [32]. Yet, this was not reflected in our findings, which may indicate a general shift e.g. 
due to increased transparency standards in the past 15 years [35, 36].  
Furthermore, HTA policy assumes that the incorporation of technologies in health systems 
could be improved by scientific rationality and unite the different stakeholders around the same 
objectives. Overall, our findings indicate that HTA policy depends on a virtuous combination between 
a science policy (e.g. good quality and adequate studies), and a health care policy (e.g. adequate 
decision-making framework). All barriers and facilitators seem related to one of these two poles. 
Hence, further research may shed light to validate these pools and which barriers and facilitators of 
each pole are the most important.  Next to that, further research could investigate how these factors 
relate to important individual beliefs that guide behaviour, which may lead to an enhanced 
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understanding of these factors in a socio-cognitive context (e.g. placing the barriers and facilitators 
under the I-Change model) [37, 38].  
This study has strength and limitations. This study is first to use conjoint analysis to quantify 
importance of barriers and facilitators to HTA usage in decision-making. Findings could serve as a first 
step to prioritise the identified barriers and facilitators from literature. One limitation may be that the 
master lists of the barriers and facilitators were not validated specifically for all four included countries 
[39]. Country-specific factors that potentially could be highly important may thus have been neglected, 
while some factors may not be relevant in the respective country. Qualitative research for each country 
could aid the findings, providing insights which factors are relevant for the respective country and why. 
However, to ensure comparability between cross-country findings, it was important for the lists of 
barriers and facilitators to be identical in this BWS study. Moreover, the identified factors were based 
on a scoping review of international literature, and were validated among British and Dutch experts. 
Another limitation regards translations; while the translation of the survey was conducted by one or 
two researchers per country, no back-translation was carried out to check its accuracy. Therefore, 
minor differences in the translations may have impaired the comparability of the survey across 
countries. Finally, due to convenience sampling, the generalisability may be limited. Policy makers 
were also found to be more likely to opt out of the survey than HTA experts. More HTA experts than 
policy makers were eventually included in the survey, implying that the average scores presented in 
this study are better capturing the perception of HTA experts. Hence, looking at the two groups of 
stakeholders separately as presented in Figure 1 and 2 is vital to get a more nuanced picture of policy 
makers specifically. An opportunity for future research regards the generalisability of findings to out-
of-sample countries, especially in emerging countries with a different decision-making context [22, 32]. 
Middle-income countries (e.g. India and Russia) compared to high-income countries (e.g. Netherlands 
and United Kingdom), have less developed HTA programs although the community that uses HTA is 
growing in middle-income countries as well [7]. Our findings may therefore not be fully transferable to 
other countries, particularly to middle-income countries. At the same time, this study included 
different healthcare systems (e.g. national health care system like the United Kingdom and social 
security system like Germany) in Western Europe. This study may be a stepping stone to draw further 




This study revealed the most important barriers and facilitators to HTA usage in the decision-making 
context, and differences in four European countries (i.e. Netherlands, Germany, France, and the UK) 
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were explored. Policy characteristics, research and researcher characteristics, and organisation and 
resources were found to be particularly important to address in order to facilitate uptake of HTA. It is 
also crucial to create a national impulse to make a political statement and create an explicit framework 
for the decision-making context to include HTA evidence. In addition, it seems that generating high 
quality HTA research in the first place is a prerequisite for adoption. Heterogeneity in the quality of 
research point out the need for enhanced international collaboration in HTA, which in turn may 




• Policy characteristics, research and researcher characteristics, and organisation and resources 
were found to be particularly important to facilitate uptake of HTA in the decision-making 
context, such as an explicit framework for decision-making and improving quality of HTA 
research. 
• Findings indicate a lack of qualified human resources to conduct or understand relevant HTA 
research within the policy organization, suggesting the need to improve capability in health 
economics by employing more health economists and providing further training for policy 
makers. 
• The most important factor seems to be an explicit framework for the decision-making context 
to include HTA evidence.  
• Generating high quality HTA research seems to be a prerequisite for adoption. Heterogeneity 
in the relative importance scores regarding the quality of research point out the need for 
enhanced international collaboration in HTA, which in turn may increase e.g. high-quality HTA 
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